Cingulate raises $5M via 9% promissory note; cash runway into Q4 2025, NDA target mid-2025

Cingulate Inc.

Net proceeds of $5.0M from $5.48M unsecured note (9% interest, 18-month maturity, $450K OID).
Cash runway extended to Q4 2025; NDA submission for CTx-1301 targeted for mid-2025.
Lender Streeterville Capital; monthly redemption cap $550K from July 2025; default triggers 15%/5% balance increases.
Guarantees from subsidiaries Cingulate Therapeutics LLC and Cingulate Works, Inc.

item 1.01 item 2.03 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.